An Investigation to Examine the Effect of the Elastomeric Surface Treatment on Protein Stability

References

1. 1.↵
   U.S. Food and Drug Administration. Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics, 1999. FDA Web site. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/container-closure-systems-packaging-human-drugs-and-biologics (accessed March 5, 2021).
2. 2.↵
   U.S. Food and Drug Administration. Guidance for Industry and FDA Staff: Use of International Standard ISO 10993-1,“Biological Evaluation of Medical Devices—Part 1: Evaluation and Testing within a Risk Management Process”, 2020. FDA Web site. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-international-standard-iso-10993-1-biological-evaluation-medical-devices-part-1-evaluation-and (accessed March 5, 2021).
3. 3.↵
   U.S. Food and Drug Administration. Guidance for Industry and FDA Staff: Technical Considerations for Additive Manufactured Medical Devices, 2017. FDA Web site. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/technical-considerations-additive-manufactured-medical-devices. (accessed March 5, 2021)
4. 4.↵
   U.S. Food and Drug Administration. Guidance for Industry and FDA Staff: Early Development Considerations for Innovative Combination Products, 2006. FDA Web site. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/early-development-considerations-innovative-combination-products (accessed March 5, 2021).
5. 5.↵
   U.S. Food and Drug Administration. Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products, 2017. FDA Web site. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-manufacturing-practice-requirements-combination-products (accessed March 5, 2021).
6. 6.↵
   1. Sacha G. A.,
   2. Saffell-Clemmer W.,
   3. Abram K.,
   4. Akers M. J.

   Practical Fundamentals of Glass, Rubber, and Plastic Sterile Packaging Systems. Pharm. Dev. Technol. 2010, 15 (1), 6–34.

   OpenUrlPubMed
7. 7.↵
   1. Rosenberg A. S.,
   2. Verthelyi D.,
   3. Cherney B. W.

   Managing Uncertainty: A Perspective on Risk Pertaining to Product Quality Attributes as They Bear on Immunogenicity of Therapeutic Proteins. J. Pharm. Sci. 2012, 101 (10), 3560–3567.

   OpenUrlPubMed
8. 8.↵
   1. Chantelau E.

   Silicone Oil Contamination of Insulin. Diabetic Med. 1989, 6 (3), 278.

   OpenUrlPubMed
9. 9.↵
   1. Chantelau E.,
   2. Berger M.,
   3. Bohlken B.

   Silicone Oil Released from Disposable Insulin Syringes. Diabetes Care 1986, 9 (6), 672–673.

   OpenUrlFREE Full Text
10. 10.↵
    1. Chantelau E.,
    2. Berger M.

    Pollution of Insulin with Silicone Oil, a Hazard of Disposable Plastic Syringes. Lancet 1985, 325 (8443), 1459.

    OpenUrl
11. 11.↵
    1. Bernstein R. K.

    Clouding and Deactivation of Clear (Regular) Human Insulin: Association with Silicone Oil from Disposable Syringes? Diabetes Care 1987, 10 (6), 786–787.

    OpenUrlFREE Full Text
12. 12.↵
    1. Baldwin R. N.

    Contamination of Insulin by Silicone Oil: A Potential Hazard of Plastic Insulin Syringes. Diabetic Med. 1988, 5 (8), 789–790.

    OpenUrlPubMed
13. 13.↵
    1. Majumdar S.,
    2. Ford B. M.,
    3. Mar K. D.,
    4. Sullivan V. J.,
    5. Ulrich R. G.,
    6. D'souza A. J. M.

    Evaluation of the Effect of Syringe Surfaces on Protein Formulations. J. Pharm. Sci. 2011, 100 (7), 2563–2573.

    OpenUrlPubMed
14. 14.↵
    1. Krayukhina E.,
    2. Tsumoto K.,
    3. Uchiyama S.,
    4. Fukui K.

    Effects of Syringe Material and Silicone Oil Lubrication on the Stability of Pharmaceutical Proteins. J. Pharm. Sci. 2015, 104 (2), 527–535.

    OpenUrlPubMed
15. 15.↵
    1. Cordes A. A.,
    2. Carpenter J. F.,
    3. Randolph T. W.

    Accelerated Stability Studies of Abatacept Formulations: Comparison of Freeze-Thawing-and Agitation-Induced Stresses. J. Pharm. Sci. 2012, 101 (7), 2307–2315.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Teska B. M.,
    2. Brake J. M.,
    3. Tronto G. S.,
    4. Carpenter J. F.

    Aggregation and Particle Formation of Therapeutic Proteins in Contact with a Novel Fluoropolymer Surface versus Siliconized Surfaces: Effects of Agitation in Vials and Prefilled Syringes. J. Pharm. Sci. 2016, 105 (7), 2053–2065.

    OpenUrl
17. 17.↵
    1. Schellekens H.,
    2. Jiskoot W.

    Erythropoietin-Associated PRCA: Still an Unsolved Mystery. J. Immunotoxicol. 2006, 3 (3), 123–130.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Boven K.,
    2. Knight J.,
    3. Bader F.,
    4. Rossert J.,
    5. Eckardt K.-U.,
    6. Casadevall N.

    Epoetin-Associated Pure Red Blood Cell Aplasia in Patients with Chronic Kidney Disease: Solving the Mystery. Nephrol. Dial. Transplant. 2005, 20 (Suppl. 3), iii33–iii40.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Gerhardt A.,
    2. Bonam K.,
    3. Bee J. S.,
    4. Carpenter J. F.,
    5. Randolph T. W.

    Ionic Strength Affects Tertiary Structure and Aggregation Propensity of a Monoclonal Antibody Adsorbed to Silicone Oil Water Interfaces. J. Pharm. Sci. 2013, 102 (2), 429–440.

    OpenUrlPubMed
20. 20.↵
    1. Gerhardt A.,
    2. Mcgraw N. R.,
    3. Schwartz D. K.,
    4. Bee J. S.,
    5. Carpenter J. F.,
    6. Randolph T. W.

    Protein Aggregation and Particle Formation in Prefilled Glass Syringes. J. Pharm. Sci. 2014, 103 (6), 1601–1612.

    OpenUrl
21. 21.↵
    1. Basu P.,
    2. Krishnan S.,
    3. Thirumangalathu R.,
    4. Randolph T. W.,
    5. Carpenter J. F.

    IgG1 Aggregation and Particle Formation Induced by Silicone-Water Interfaces on Siliconized Borosilicate Glass Beads: A Model for Siliconized Primary Containers. J. Pharm. Sci. 2013, 102 (3), 852–865.

    OpenUrl
22. 22.↵
    1. Thirumangalathu R.,
    2. Krishnan S.,
    3. Ricci M. S.,
    4. Brems D. N.,
    5. Randolph T. W.,
    6. Carpenter J. F.

    Silicone Oil- and Agitation-Induced Aggregation of a Monoclonal Antibody in Aqueous Solution. J. Pharm. Sci. 2009, 98 (9), 3167–3181.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Mehta S. B.,
    2. Lewus R.,
    3. Bee J. S.,
    4. Randolph T. W.,
    5. Carpenter J. F.

    Gelation of a Monoclonal Antibody at the Silicone Oil Water Interface and Subsequent Rupture of the Interfacial Gel Results in Aggregation and Particle Formation. J. Pharm. Sci. 2015, 104 (4), 1282–1290.

    OpenUrl
24. 24.↵
    1. Jones L. S.,
    2. Kaufmann A.,
    3. Middaugh C. R.

    Silicone Oil Induced Aggregation of Proteins. J. Pharm. Sci. 2005, 94 (4), 918–927.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Ludwig D. B.,
    2. Carpenter J. F.,
    3. Hamel J.,
    4. Randolph T. W.

    Protein Adsorption and Excipient Effects on Kinetic Stability of Silicone Oil Emulsions. J. Pharm. Sci. 2010, 99 (4), 1721–1733.

    OpenUrlPubMedWeb of Science
26. 26.↵
    1. Mahler H.-C.,
    2. Müller R.,
    3. Frieβ W.,
    4. Delille A.,
    5. Matheus S.

    Induction and Analysis of Aggregates in a Liquid IgG1-Antibody Formulation. Eur. J. Pharm. Biopharm. 2005, 59 (3), 407–417.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Colombie S.,
    2. Gaunand A.,
    3. Lindet B.

    Lysozyme Inactivation under Mechanical Stirring: Effect of Physical and Molecular Interfaces. Enzyme Microb. Technol. 2001, 28 (9–10), 820–826.

    OpenUrlPubMed
28. 28.↵
    1. Jorgensen L.,
    2. Bennedsen P.,
    3. Hoffmann S. V.,
    4. Krogh R. L.,
    5. Pinholt C.,
    6. Groenning M.,
    7. Hostrup S.,
    8. Bukrinsky J. T.

    Adsorption of Insulin with Varying Self-Association Profiles to a Solid Teflon Surface—Influence on Protein Structure, Fibrillation Tendency and Thermal Stability. Eur. J. Pharm. Sci. 2011, 42 (5), 509–516.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Nayak A.,
    2. Dutta A. K.,
    3. Belfort G.

    Surface-Enhanced Nucleation of Insulin Amyloid Fibrillation. Biochem. Biophys. Res. Commun. 2008, 369 (2), 303–307.

    OpenUrlPubMed
30. 30.↵
    1. Yan Y.,
    2. Seeman D.,
    3. Zheng B.,
    4. Kizilay E.,
    5. Xu Y.,
    6. Dubin P. L.

    pH-Dependent Aggregation and Disaggregation of Native β -Lactoglobulin in Low Salt. Langmuir 2013, 29 (14), 4584–4593.

    OpenUrl
31. 31.↵
    Bristol-Myers Squibb. Orencia Package Insert. http://packageinserts.bms.com/pi/pi_orencia.pdf (accessed December 1, 2017).
32. 32.↵
    UniProtKB—P02768 (ALBU_HUMAN). https://www.uniprot.org/uniprot/P02768. (accessed December 15, 2018).
33. 33.↵
    1. Liu H. F.,
    2. Ma J.,
    3. Winter C.,
    4. Bayer R.

    Recovery and Purification Process Development for Monoclonal Antibody Production. mAbs 2010, 2 (5), 480–499.

    OpenUrlCrossRefPubMedWeb of Science
34. 34.↵
    1. Wang W.,
    2. Ignatius A. A.,
    3. Thakkar S. V.

    Impact of Residual Impurities and Contaminants on Protein Stability. J. Pharm. Sci. 2014, 103 (5), 1315–1330.

    OpenUrl
35. 35.↵
    1. Mahler H.,
    2. Friess W.,
    3. Grauschopf U.,
    4. Kiese S.

    Protein Aggregation: Pathways, Induction Factors and Analysis. J. Pharm. Sci. 2009, 98 (9), 2909–2934.

    OpenUrlCrossRefPubMed
36. 36.↵
    1. Randolph T. W.,
    2. Schiltz E.,
    3. Sederstrom D.,
    4. Steinmann D.,
    5. Mozziconacci O.,
    6. Schöneich C.,
    7. Freund E.,
    8. Ricci M. S.,
    9. Carpenter J. F.,
    10. Lengsfeld C. S.

    Do Not Drop: Mechanical Shock in Vials Causes Cavitation, Protein Aggregation, and Particle Formation. J. Pharm. Sci. 2015, 104 (2), 602–611.

    OpenUrl
37. 37.↵
    1. Krielgaard L.,
    2. Jones L. S.,
    3. Randolph T. W.

    Effect of Tween 20 on Freeze-Thawing- and Agitation-Induced Aggregation of Recombinant Human Factor XIII. J. Pharm. Sci. 1998, 87 (12), 1593–1603.

    OpenUrl
38. 38.↵
    1. Kiese S.,
    2. Papppenberger A.,
    3. Friess W.,
    4. Mahler H.

    Shaken, Not Stirred: Mechanical Stress Testing of an IgG1 Antibody. J. Pharm. Sci. 2008, 97 (10), 4347–4366.

    OpenUrlCrossRefPubMedWeb of Science
39. 39.↵
    1. Chou D. K.,
    2. Krishnamurthy R.,
    3. Randolph T. W.,
    4. Carpenter J. F.,
    5. Manning M. C.

    Effects of Tween 20 and Tween 80 on the Stability of Albutropin during Agitation. J. Pharm. Sci. 2005, 94 (6), 1368–1381.

    OpenUrlCrossRefPubMedWeb of Science
40. 40.↵
    1. Bam N. B.,
    2. Cleland J. L.,
    3. Yang J.,
    4. Manning M. C.,
    5. Carpenter J. F.,
    6. Kelley R. F.,
    7. Randolph T. W.

    Tween Protects Recombinant Human Growth Hormone against Agitation-Induced Damage via Hydrophobic Interactions. J. Pharm. Sci. 1998, 87 (12), 1554–1559.

    OpenUrlCrossRefPubMedWeb of Science
41. 41.↵
    1. Roberts C. J.

    Therapeutic Protein Aggregation: Mechanisms, Design, and Control. Trends Biotechnol. 2014, 32 (7), 372–380.

    OpenUrlCrossRefPubMed
42. 42.↵
    1. Hermeling S.,
    2. Crommelin D. J. A.,
    3. Schellekens H.,
    4. Jiskoot W.

    Structure-Immunogenicity Relationships of Therapeutic Proteins. Pharm. Res. 2004, 21 (6), 897–903.

    OpenUrlCrossRefPubMedWeb of Science
43. 43.↵
    1. Rosenberg A. S.

    Effects of Protein Aggregates: An Immunologic Perspective. AAPS J. 2006, 8 (3), E501–507.

    OpenUrlCrossRefPubMedWeb of Science
44. 44.↵
    1. Joubert M. K.,
    2. Hokom M.,
    3. Eakin C.,
    4. Zhou L.,
    5. Deshpande M.,
    6. Baker M. P.,
    7. Goletz T. J.,
    8. Kerwin B. A.,
    9. Chirmule N.,
    10. Narhi L. O.,
    11. Jawa V.

    Highly Aggregated Antibody Therapeutics Can Enhance the in Vitro Innate and Late-Stage T-Cell Immune Responses. J. Biol. Chem. 2012, 287 (30), 25266–25279.

    OpenUrlAbstract/FREE Full Text
45. 45.↵
    1. Moussa E. M.,
    2. Panchal J. P.,
    3. Moorthy B. S.,
    4. Blum J. S.,
    5. Joubert M. K.,
    6. Narhi L. O.,
    7. Topp E. M.

    Immunogenicity of Therapeutic Protein Aggregates. J. Pharm. Sci. 2016, 105 (2), 417–430.

    OpenUrl
46. 46.↵
    1. Markovic I.

    Evaluation of Safety and Quality Impact of Extractable and Leachable Substances in Therapeutic Biologic Protein Products: A Risk-Based Perspective. Expert Opin. Drug Saf. 2007, 6 (5), 487–491.

    OpenUrlCrossRefPubMedWeb of Science
47. 47.↵
    1. Luo Q.,
    2. Joubert M. K.,
    3. Stevenson R.,
    4. Ketchem R. R.,
    5. Narhi L. O.,
    6. Wypych J.

    Chemical Modifications in Therapeutic Protein Aggregates Generated under Different Stress Conditions. J. Biol. Chem. 2011, 286 (28), 25134–25144.

    OpenUrlAbstract/FREE Full Text
48. 48.↵
    1. Men L.,
    2. Wang Y.

    The Oxidation of Yeast Alcohol Dehydrogenase-1 by Hydrogen Peroxide in Vitro. J. Proteome Res. 2007, 6 (1), 216–225.

    OpenUrlCrossRefPubMed
49. 49.↵
    1. Pan H.,
    2. Chen K.,
    3. Chu L.,
    4. Kinderman F.,
    5. Apostol I.,
    6. Huang G.

    Methionine Oxidation in Human IgG2 Fc Decreases Binding Affinities to Protein A and FcRn. Protein Sci. 2009, 18 (2), 424–433.

    OpenUrlCrossRefPubMedWeb of Science
50. 50.↵
    1. Finley E. L.,
    2. Dillon J.,
    3. Crouch R. K.,
    4. Schey K. L.

    Identification of Tryptophan Oxidation Products in Bovine α‐Crystallin. Protein Sci. 1998, 7 (11), 2391–2397.

    OpenUrlCrossRefPubMedWeb of Science
51. 51.↵
    1. Schöneich C.

    Mechanisms of Metal-Catalyzed Oxidation of Histidine to 2-Oxo-Histidine in Peptides and Proteins. J. Pharm. Biomed. Anal. 2000, 21 (6), 1093–1097.

    OpenUrlCrossRefPubMedWeb of Science
52. 52.↵
    1. Ji J. A.,
    2. Zhang B.,
    3. Cheng W.,
    4. Wang Y. J.

    Methionine, Tryptophan, and Histidine Oxidation in a Model Protein, PTH: Mechanisms and Stabilization. J. Pharm. Sci. 2009, 98 (12), 4485–4500.

    OpenUrlCrossRefPubMed
53. 53.↵
    1. Fang L.,
    2. Zhao C.

    Modeling the Permeation Rates of Organic Migrants through a Fluoropolymer Film. PDA J. Pharm. Sci. Technol. 2019, 73 (1), 70–82.

    OpenUrlAbstract/FREE Full Text